Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study

ConclusionsSubcutaneous IgPro20 manual push infusions at flow rates up to 2.0 mL/min were well tolerated and reduced infusion time in treatment-experienced patients with PID.Trial RegistrationNCT03033745

http://link.springer.com/10.1007/s10875-020-00876-6

Source: Journal of Clinical Immunology - October 5, 2020 Category: Allergy & Immunology Source Type: research

More News: Allergy & Immunology | Primary Immunodeficiency Disease | Study